Serine

Serine

SCHEMBL418634

NCC(=O)OC(=O)[C@@H](N)CS.N[C@@H](CO)C(=O)O

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.48
SLC7A11 Q9UPY5 1/20 0.48
SLC1A1 P43005 1/20 0.35
ENPEP Q07075 4/20 0.32
GSR P00390 1/20 0.32
CPB2 Q96IY4 1/20 0.30
GRIK1 P39086 1/20 0.30
GRIK2 Q13002 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL361160 0.88 PTGS1 (0.44) PTGS1SLC7A11ENPEPCPB2
SCHEMBL5149928 0.88 PTGS1 (0.44) PTGS1SLC7A11ENPEPCPB2
Serine SCHEMBL1064689 0.84 SLC1A1 (0.43) PTGS1SLC7A11SLC1A1GSRGRIK1
Serine SCHEMBL3961258 0.83 SLC1A5 (0.36) PTGS1SLC7A11SLC1A1GSRGRIK1
Serine SCHEMBL3052910 0.82 SLC1A5 (0.35) PTGS1SLC7A11SLC1A1GSR
SCHEMBL4394836 0.82 SLC1A1 (0.31) SLC1A1
SCHEMBL117468 0.82 SLC1A1 (0.31) SLC1A1
SCHEMBL3075848 0.81 PTGS1 (0.43) PTGS1SLC7A11
Serine SCHEMBL4887746 0.81 PTGS1 (0.43) PTGS1SLC7A11SLC1A1ENPEPGRIK1
Serine SCHEMBL6666261 0.81 SLC7A5 (0.38) PTGS1SLC7A11SLC1A1GSRGRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024086683-A2 FLAGELLIN EPITOPE PEPTIDES AND USES THEREOF THE UAB RESEARCH FOUNDATION (US) 2024-04-25 WO disclosed
CN-117898989-A Composition for repairing skin barrier and application thereof 上海家化联合股份有限公司 2024-04-19 CN disclosed
CN-117898990-A Composition containing collagen and sweet wormwood herb extract and application thereof 上海家化联合股份有限公司 2024-04-19 CN disclosed
US-20220373561-A1 TRANSFORMATIONAL IMMUNE DIAGNOSTICS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-11-24 US disclosed
US-20220010301-A1 METHODS OF SELECTING FUNCTIONAL INTERFACE MIMICS, AND COMPOSITIONS THEREOF Cowper Sciences Inc. 2022-01-13 US disclosed
CN-113677691-A Method for selecting functional interface simulant and composition thereof 库博科学公司 2021-11-19 CN disclosed
WO-2021158533-A1 TRANSFORMATIONAL IMMUNE DIAGNOSTICS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2021-08-12 WO disclosed
US-20210223257-A1 METHOD AND SYSTEM FOR DETERMINING MICROSATELLITE INSTABILITY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-07-22 US disclosed
US-11067582-B2 Peptide array quality control ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2021-07-20 US disclosed
US-20210199654-A1 ARRAY AND METHOD OF USE UNIV ARIZONA STATE (US) 2021-07-01 US disclosed
WO-2010148365-A2 COMPOUND ARRAYS FOR SAMPLE PROFILING THE ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2010-12-23 WO disclosed
US-20100248977-A1 Immobilizing an Entity in a Desired Orientation on a Support Material ARIZONA BOARD OF REGENTS ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2010-09-30 US disclosed
WO-2010111299-A2 SYNTHETIC ANTIBODIES THE ARIZONA BOARD OF REGENTS A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2010-09-30 WO disclosed
EP-2205974-A2 IMMOBILIZING AN ENTITY IN A DESIRED ORIENTATION ON A SUPPORT MATERIAL Arizona Board Of Regents, A Body Corporate Acting For And On Behalf Of Northern Arizona University (US) 2010-07-14 EP disclosed
WO-2010028214-A2 SCREENING METHOD TO IDENTIFY MOLECULES HAVING THE ABILITY TO MODULATE THE ACTIVITY OF A CATALYST ARIZONA BOARD OF REGENTS ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2010-03-11 WO disclosed
WO-2009140039-A2 SYNTHETIC ANTIBODIES THE ARIZONA BOARD OF REGENTS ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2009-11-19 WO disclosed
EP-2076614-A2 SYNTHETIC ANTIBODIES The Arizona Board of Regents, A Body Corporate Of the State of Arizona acting for and on behalf Of Arizona State University (US) 2009-07-08 EP disclosed
WO-2009082417-A2 IMMOBILIZING AN ENTITY IN A DESIRED ORIENTATION ON A SUPPORT MATERIAL ARIZONA BOARD OF REGENTS ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2009-07-02 WO disclosed
WO-2008048970-A2 SYNTHETIC ANTIBODIES THE ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2008-04-24 WO disclosed
US-20070292379-A1 HAIR TREATING AGENT COMPRISING CORNEOCYTE PROTEINS OR CORNEOCYTE POLYPEPTIDES HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2007-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070292379-A1 HAIR TREATING AGENT COMPRISING CORNEOCYTE PROTEINS OR CORNEOCYTE POLYPEPTIDES KRT18, S100A4, S100P PTGS1 3041/4885SLC7A11 2307/4885SLC1A1 3106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.